Login / Register The Most Trusted Name in Medical Education

Neurology

From Alzheimer's to Epilepsy and Multiple Sclerosis Elsevier's Office of Continuing Medical Education offers complimentary CME courses for a variety of neurology activities.

910720 116 x 140

An Update on Scientific Advances and Clinical Strategies in Alzheimer’s Disease: Conference Reporter from AD/PD™ 2017

Format: Conference Reporter

The Alzheimer’s & Parkinson’s Diseases (AD/PD™) 13th International Conference was held in Vienna, Austria, March 29 to April 2, 2017. The conference attracts international medical and scientific professionals worldwide and is at the forefront of unraveling the mechanisms and improving the treatment of neurodegenerative diseases, including Alzheimer’s disease (AD). In this activity, 2 experts summarize the key learnings from this year’s conference focusing on AD.

Take Course »

Credits: 1.00 AMA PRA Category 1 Credit(s)™
AAN 116 x 140

Applying New Science to Improve Outcomes for Patients with Multiple Sclerosis

Format: Conference Reporter

 This CME program will feature content presented at the the 69th Annual American Academy of Neurology (AAN) Meeting held in Boston, Massachusetts. Three expert faculty will analyze recent therapeutic advances in the treatment and management of patients with multiple sclerosis. The clinical relevance of emerging and emerged trial data will be reviewed. Faculty will discuss strategies for utilizing the multidisciplinary team approach to develop and implement personalized treatment plans, accommodating patient-specific disease characteristics. Upon completion of the activity, learners will have a better grasp of evolving science in the field of multiple sclerosis as it relates to clinical practice.

Take Course »

 

Credits: 1.00 AMA PRA Category 1 Credit(s)™
910645 116 x 140

An Update on Scientific Advances and Clinical Strategies in Alzheimer’s Disease: Report from AAIC 2016

Format: Medical Meeting Reporter

The Alzheimer's Association International Conference® 2016 (AAIC®) annual meeting was held in Toronto, Canada, July 22-28, 2016. AAIC is the world's largest forum for the dementia research community. Researchers, clinicians, care providers, and students from more than 70 countries gather at AAIC to network and discuss the latest dementia study results, theories, and discoveries. In this activity, 2 experts summarize the key learnings from this year’s conference.

Register »

Credits: 0.75 AMA PRA Category 1 Credit(s)™ or 0.75 AANP Contact Hour(s)
910627e 116 x 140

In Focus: The Amyloid-Tau Relationship in the Pathophysiology of Alzheimer’s Disease

Format: Webcast

The pathophysiology of Alzheimer’s disease (AD) involves both amyloid and tau proteins; the exploration of the respective roles of these proteins in neuronal loss and neurodegeneration has important implications for future therapeutic interventions. PET imaging of amyloid and tau plays a critical role in understanding neurodegeneration patterns and clinical manifestations of AD.

Register »

Credits: 1.5 Royal College of Physicians and Surgeons of Canada Section 1 Maintenance of Certification
910644 116 x 140

ECTRIMS 2016: Optimally Managing Patients with Multiple Sclerosis through Individualized Treatment Options

Format: Medical Meeting Reporter

This CME program focuses on content presented during 2016 ECTRIMS Annual Meeting in London, United Kingdom on September 14 – 17, 2016. This activity educates healthcare providers involved in the management of patients with multiple sclerosis (MS) with the goal of presenting the most comprehensive analysis for clinical decision-making. This includes the role of the comprehensive healthcare team in the initiation of therapy, as well as effectively communicating therapeutic decisions to the patient. Faculty members assess patient-specific treatment plans to improve outcomes for patients with multiple sclerosis.

Register »

Credits: 1.00 AMA PRA Category 1 Credit(s)™ or 1.0 AANP Contact Hour(s)
910670 116 x 140

ECTRIMS 2016: Utilizing Individualized Treatment Plans to Optimally Manage Patients with Multiple Sclerosis

Format: Medical Meeting Reporter

This CME program will focus on the new and emerging therapeutic options for the management of patients with multiple sclerosis (MS) that were discussed at the 2016 ECTRIMS Annual Meeting in London, United Kingdom from September 14 – 17, 2016. This activity will educate healthcare providers about novel techniques and optimal management strategies for their patients with multiple sclerosis. The expert faculty will discuss the science behind new and emerging therapies, the efficacy and safety data supporting new biomarkers, and the role of biomarkers alongside traditional MS treatment options. Upon completion of this CME activity, the multidisciplinary team will be equipped with the information needed to create tailored treatment plans and improve outcomes.

Register »

Credits: 1.00 AMA PRA Category 1 Credit(s)™
2016 CTAD banner 116x140

An Update on Scientific Advances and Clinical Strategies in Alzheimer’s Disease: Report From CTAD 2016

Format: Medical Meeting Reporter

The 9th meeting of Clinical Trials on Alzheimer’s Disease (CTAD) was held in San Diego, California, December 8-10, 2016. CTAD has become one of the most important scientific meetings in the Alzheimer’s disease (AD) area. It brings together today’s global leaders in AD to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of AD treatments. In this activity, 2 experts summarize the key learnings from this year’s conference. 

Register »

Credits: 0.75 AMA PRA Category 1 Credit(s)™
SNO 116x141

New Considerations for the Treatment of Glioblastoma Multiforme: Evaluating the Potential for Immune Checkpoint Inhibitors

Format: Webcast

The content for this activity is based on the satellite symposium, “New Considerations for the Treatment of Glioblastoma Multiforme: Evaluating the Potential for Immune Checkpoint Inhibitors”, that was presented at the 21st Annual Meeting of the Society for Neuro-Oncology in Scottsdale, Arizona on November 17, 2016. Glioblastoma multiforme (GBM) remains one of the most feared of all malignancies due to its aggressive nature and correspondingly low survival rates. Recently, immunotherapies – particularly immune checkpoint inhibitors – have shown promise in treating patients with GBM in cases where conventional treatment options have failed. This archived symposium activity will provide participants with the opportunity to optimize the diagnosis and management of patients with GBM, including new data and remaining challenges resulting from recent clinical trials in the use of immune checkpoint inhibitors.

Take Course »

Credits: 1.50 AMA PRA Category 1 Credit(s)™
2016 Alzheimers Disease in Primary Care banner116x140

Alzheimer’s Disease in Primary Care: The Significance of Early Detection, Diagnosis, and Intervention

Format: Webcast

The field of Alzheimer’s disease (AD) is undergoing a profound and rapid change: clinical trials have been redesigned to focus on individuals in the earliest stages of the disease and are including more sensitive measurement tools to better capture changes in cognition and other outcomes. Trial participants undergo PET imaging for amyloid load as a hallmark for dementia, as well as genetic testing to determine likelihood of disease progression and response to therapeutic intervention. Large national and international registries have been established to capture those at risk and to follow their development of cognitive changes longitudinally. Understanding that the disease process starts at least a decade or more before the onset of symptoms has prompted the development of therapeutic interventions acting very early in the disease cascade. For all these reasons, recognizing and diagnosing AD early offers affected individuals and their caregivers the best chance for care planning, access to available symptomatic treatment and community resources, as well as involvement with clinical trials and access to new therapies when they become available. Primary care clinicians play a pivotal role in the early recognition of cognitive impairment in their patients.

Take Course »

Credits: 1.00 AMA PRA Category 1 Credit(s)™
Elsevier CNS 2016 10 Web 140x116

Joining a Conversation on Improving the Multidisciplinary Management of SMA: Now and in the Future

Format: Webcast

The content for this activity is based on the satellite symposium, “Joining a Conversation on Improving the Multidisciplinary Management of SMA: Now and in the Future”, that was presented at the 45th Child Neurology Society Annual Meeting in Vancouver, Canada, on October 27, 2016.

This presentation will provide an overview of the clinical picture of SMA and its natural history, offer guidance on the diagnosis and classification of SMA by neurological examination and gene profiling, discuss the appropriate use of available assessment tools and outcomes measures, and review the emerging treatment landscape via the latest scientific data. Using interactive plenary sessions and selected patient case presentations, our expert panel will encourage the exchange of views and opinions on the rapidly evolving SMA treatment landscape.

Take Course »

Credits: 1.50 AMA PRA Category 1 Credit(s)™
AAPMR 116x140

Spasticity Video Challenge: A Look at Methods for Addressing Difficult Cases

Format: Webcast

This symposium archive will provide participants with the opportunity to assess remaining challenges in the care of patients with spasticity. In addition to reviewing appropriate use of chemodenervation and other treatments, this activity will also highlight techniques for improved communication between physicians and patients regarding the causes of functional impairments, individualized treatment options, customized goals of treatment, and the need for post-intervention rehabilitation and home programs via interactive video case presentations.

The content for this activity is based on the satellite symposium, Spasticity Video Challenge: A Look at Methods for Addressing Difficult Cases, that was presented at the AAPM&R Annual Assembly in New Orleans, Louisiana on October 22, 2016.

Take Course »

Credits: 1.50 AMA PRA Category 1 Credit(s)™
FH 116 x 140

The Role of PCSK9 Inhibitors in Managing Patients With Familial Hypercholesterolemia

Format: Webcast

This CME activity will focus on the management of patients with familial hypercholesterolemia and the role of PCSK9 inhibitors in this therapeutic area. Expert faculty will review the science of PCSK9, the updated standards of care for the diagnosis, and FH scoring and management of patients with familial hypercholesterolemia. Clinical trial data of PCSK9 inhibitors for the treatment of familial hypercholesterolemia, including long-term efficacy and safety data, will be analyzed. The faculty will guide physicians on how to implement a multidisciplinary approach to optimally manage patient-specific disease to improve outcomes for patients with familial hypercholesterolemia. Upon completing this activity, physicians will gain knowledge on the most up-to-date care for this cohort of patients.

Take Course »

Credits: 1.00 AMA PRA Category 1 Credit(s)™